drugset / Trial / NCT04895579
Lung Cancer With Copanlisib and Durvalumab
NaSingle-groupOpen-labelTreatment
Summary
The current study focuses on unresectable stage III non-small cell lung cancer (NSCLC) patients who are starting Durvalumab consolidation after concurrent chemoradiation with a goal of cure. The overall hypothesis of this study is that the addition of Copanlisib to Durvalumab will be well-tolerated at a biweekly schedule. It will test whether the addition of Copanlisib to Durvalumab can overcome resistance to Durvalumab.
Timeline
- Start
- 2021-05-12
- Primary completion
- 2025-11-12
- Completion
- 2025-11-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Copanlisib | Small molecule | 30 mg | Intravenous |
| Subject | Copanlisib | Small molecule | 60 mg | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |